PDCD1 and chronic obstructive pulmonary disease: Interestingly, patients with chronic obstructive pulmonary disease (COPD) are more sensitive to PD-1/PD-L1 inhibitors (2), which may be related to the changes in immune micro-environment secondary to the disease process.